Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

详细信息    查看全文

• 作者：Jeeyun Lee (1)
  Yong Sang Hong (2)
  Jung Yong Hong (1)
  Se Won Han (3)
  Tae Won Kim (2)
  Hye Jin Kang (4)
  Tae You Kim (3)
  Kyu-pyo Kim (2)
  Suk Hyung Kim (5)
  In-Gu Do (5)
  Kyoung-Mee Kim (5)
  Insuk Sohn (6)
  Se Hoon Park (1)
  Joon Oh Park (1)
  Ho Yeong Lim (1)
  Yong Beom Cho (7)
  Woo Yong Lee (7)
  Seong Hyeon Yun (7)
  Hee Cheol Kim (7)
  Young Suk Park (1)
  Won Ki Kang (1)
  
• 关键词：Simvastatin ; Cetuximab ; KRAS ; Colorectal cancer ; RAS signature
• 刊名：Investigational New Drugs
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：32
• 期：3
• 页码：535-541
• 全文大小：
• 参考文献：1. Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408鈥?417 CrossRef
  2. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697鈥?705 CrossRef
  3. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757鈥?765 CrossRef
  4. Lee J, Lee I, Han B et al (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103:674鈥?88 CrossRef
  5. Lee J, Jung KH, Park YS et al (2009) Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 64:657鈥?63 CrossRef
  6. Loboda A, Nebozhyn M, Klinghoffer R et al (2010) A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics 3:26 CrossRef
  7. Kim ST (2011) Lim do H, Jang KT et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10:1993鈥?999 CrossRef
  8. Geiss GK, Bumgarner RE, Birditt B et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317鈥?25 CrossRef
  9. Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303鈥?12 CrossRef
  10. De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753鈥?62 CrossRef
  11. Sartore-Bianchi A, Martini M, Molinari F et al (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851鈥?857 CrossRef
  12. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308鈥?324 CrossRef
  13. Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091鈥?096 CrossRef
  14. De Roock W, De Vriendt V, Normanno N et al (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594鈥?03 CrossRef
  15. Loboda A, Nebozhyn M, Cheng C et al (2009) Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther 86:92鈥?6 CrossRef
  
• 作者单位：Jeeyun Lee (1)
  Yong Sang Hong (2)
  Jung Yong Hong (1)
  Se Won Han (3)
  Tae Won Kim (2)
  Hye Jin Kang (4)
  Tae You Kim (3)
  Kyu-pyo Kim (2)
  Suk Hyung Kim (5)
  In-Gu Do (5)
  Kyoung-Mee Kim (5)
  Insuk Sohn (6)
  Se Hoon Park (1)
  Joon Oh Park (1)
  Ho Yeong Lim (1)
  Yong Beom Cho (7)
  Woo Yong Lee (7)
  Seong Hyeon Yun (7)
  Hee Cheol Kim (7)
  Young Suk Park (1)
  Won Ki Kang (1)
  
  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul, 135-710, Korea
  2. Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
  3. Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
  4. Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
  5. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  6. Samsung Cancer Research Institute, Samsung Medical Center, Seoul, South Korea
  7. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  
• ISSN：1573-0646

文摘